BIOMAT Database Logo BIOMAT Database Logo

Long-lasting remission induced by rituximab in two cases of refractory autoimmune haemolytic anaemia due to cold agglutinins. 2009

Massimiliano Palombi, and Pasquale Niscola, and Malgorzata Monika Trawinska, and Laura Scaramucci, and Marco Giovannini, and Alessio Perrotti, and Paolo de Fabritiis

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069283 Rituximab A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS. CD20 Antibody, Rituximab,GP2013,IDEC-C2B8,IDEC-C2B8 Antibody,Mabthera,Rituxan,IDEC C2B8,IDEC C2B8 Antibody,Rituximab CD20 Antibody
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000744 Anemia, Hemolytic, Autoimmune Acquired hemolytic anemia due to the presence of AUTOANTIBODIES which agglutinate or lyse the patient's own RED BLOOD CELLS. Anemia, Hemolytic, Idiopathic Acquired,Autoimmune Haemolytic Anaemia,Autoimmune Hemolytic Anemia,Cold Agglutinin Disease,Hemolytic Anemia, Autoimmune,Acquired Autoimmune Hemolytic Anemia,Anemia, Hemolytic, Cold Antibody,Cold Antibody Disease,Cold Antibody Hemolytic Anemia,Idiopathic Autoimmune Hemolytic Anemia,Agglutinin Disease, Cold,Anaemia, Autoimmune Haemolytic,Anemia, Autoimmune Hemolytic,Autoimmune Haemolytic Anaemias,Autoimmune Hemolytic Anemias,Cold Agglutinin Diseases,Cold Antibody Diseases,Haemolytic Anaemia, Autoimmune
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

Massimiliano Palombi, and Pasquale Niscola, and Malgorzata Monika Trawinska, and Laura Scaramucci, and Marco Giovannini, and Alessio Perrotti, and Paolo de Fabritiis
Long lasting remission by rituximab in a patient with primary cold agglutinin autoimmune haemolytic anaemia.
November 2011, Wiener klinische Wochenschrift,
Massimiliano Palombi, and Pasquale Niscola, and Malgorzata Monika Trawinska, and Laura Scaramucci, and Marco Giovannini, and Alessio Perrotti, and Paolo de Fabritiis
Haemolytic anaemia due to cold agglutinins caused by psittacosis.
June 1989, The Netherlands journal of medicine,
Massimiliano Palombi, and Pasquale Niscola, and Malgorzata Monika Trawinska, and Laura Scaramucci, and Marco Giovannini, and Alessio Perrotti, and Paolo de Fabritiis
Daratumumab in rituximab-refractory autoimmune haemolytic anaemia.
September 2021, British journal of haematology,
Massimiliano Palombi, and Pasquale Niscola, and Malgorzata Monika Trawinska, and Laura Scaramucci, and Marco Giovannini, and Alessio Perrotti, and Paolo de Fabritiis
Essential eryoglobulinaemia and acquired haemolytic anaemia due to cold agglutinins.
May 1959, Australasian annals of medicine,
Massimiliano Palombi, and Pasquale Niscola, and Malgorzata Monika Trawinska, and Laura Scaramucci, and Marco Giovannini, and Alessio Perrotti, and Paolo de Fabritiis
Rituximab: a very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD20-positive, low-grade non-Hodgkin's lymphoma.
March 2001, British journal of haematology,
Massimiliano Palombi, and Pasquale Niscola, and Malgorzata Monika Trawinska, and Laura Scaramucci, and Marco Giovannini, and Alessio Perrotti, and Paolo de Fabritiis
Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab).
July 2001, British journal of haematology,
Massimiliano Palombi, and Pasquale Niscola, and Malgorzata Monika Trawinska, and Laura Scaramucci, and Marco Giovannini, and Alessio Perrotti, and Paolo de Fabritiis
Virus pneumonia, cold agglutinins and haemolytic anaemia.
May 1955, Canadian Medical Association journal,
Massimiliano Palombi, and Pasquale Niscola, and Malgorzata Monika Trawinska, and Laura Scaramucci, and Marco Giovannini, and Alessio Perrotti, and Paolo de Fabritiis
[The effectiveness of rituximab in refractory autoimmune thrombocytopenic purpura and haemolytic anaemia].
January 2007, Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria,
Massimiliano Palombi, and Pasquale Niscola, and Malgorzata Monika Trawinska, and Laura Scaramucci, and Marco Giovannini, and Alessio Perrotti, and Paolo de Fabritiis
Autoimmune haemolytic anaemia due to Omeprazole.
February 2007, Irish medical journal,
Massimiliano Palombi, and Pasquale Niscola, and Malgorzata Monika Trawinska, and Laura Scaramucci, and Marco Giovannini, and Alessio Perrotti, and Paolo de Fabritiis
Autoimmune haemolytic anaemia due to immunodeficiency.
November 2022, BMJ case reports,
Copied contents to your clipboard!